Critical Needs in Advancing Shigella Vaccines for Global Health.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 34558631.
- Also identified by DOI 10.1093/infdis/jiab462 and PMC identifier 9071279.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Advancing new O-antigen-based <i>Shigella</i> vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.
Medical subject headings
- Dysentery, Bacillary
- Enterotoxigenic Escherichia coli
- Shigella Vaccines
- Vaccines